Guangxi Sun

1.5k total citations
84 papers, 614 citations indexed

About

Guangxi Sun is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Guangxi Sun has authored 84 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pulmonary and Respiratory Medicine, 23 papers in Molecular Biology and 20 papers in Cancer Research. Recurrent topics in Guangxi Sun's work include Prostate Cancer Treatment and Research (41 papers), Prostate Cancer Diagnosis and Treatment (25 papers) and Renal cell carcinoma treatment (22 papers). Guangxi Sun is often cited by papers focused on Prostate Cancer Treatment and Research (41 papers), Prostate Cancer Diagnosis and Treatment (25 papers) and Renal cell carcinoma treatment (22 papers). Guangxi Sun collaborates with scholars based in China, United States and Hong Kong. Guangxi Sun's co-authors include Jinge Zhao, Pengfei Shen, Junru Chen, Hao Zeng, Sha Zhu, Xingming Zhang, Xudong Zhu, Ni Chen, Jiandong Liu and Jindong Dai and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The FASEB Journal.

In The Last Decade

Guangxi Sun

73 papers receiving 611 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guangxi Sun China	15	344	190	156	116	106	84	614
Marcel Trautmann Germany	19	430 1.3×	181 1.0×	216 1.4×	96 0.8×	93 0.9×	48	781
Giovanna De Maglio Italy	15	364 1.1×	308 1.6×	238 1.5×	109 0.9×	216 2.0×	48	815
Joana Vieira Portugal	14	293 0.9×	220 1.2×	344 2.2×	85 0.7×	134 1.3×	39	701
Alessandra Bisagni Italy	16	259 0.8×	285 1.5×	172 1.1×	106 0.9×	124 1.2×	51	765
Sarah Dumont France	16	386 1.1×	309 1.6×	158 1.0×	97 0.8×	116 1.1×	64	783
Roger Paul Germany	15	309 0.9×	85 0.4×	159 1.0×	200 1.7×	60 0.6×	23	567
Nadine Hanna France	17	528 1.5×	227 1.2×	257 1.6×	91 0.8×	77 0.7×	53	934
Carmine D’Aniello Italy	17	350 1.0×	147 0.8×	242 1.6×	239 2.1×	167 1.6×	33	720
Tomohiro Fujii Japan	19	310 0.9×	261 1.4×	216 1.4×	155 1.3×	65 0.6×	47	887
Michael Kolinsky Canada	13	572 1.7×	361 1.9×	182 1.2×	84 0.7×	197 1.9×	54	824

Countries citing papers authored by Guangxi Sun

Since Specialization

Citations

This map shows the geographic impact of Guangxi Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangxi Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangxi Sun more than expected).

Fields of papers citing papers by Guangxi Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangxi Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangxi Sun. The network helps show where Guangxi Sun may publish in the future.

Co-authorship network of co-authors of Guangxi Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Guangxi Sun. A scholar is included among the top collaborators of Guangxi Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangxi Sun. Guangxi Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yuan, et al.. (2025). Mapping the current research landscape of metformin in cancer based on bibliometric analysis. Discover Oncology. 16(1). 1522–1522.

Chen, Junru, Guangxi Sun, Xingming Zhang, et al.. (2025). The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate. The Prostate. 85(7). 659–669.

Zhao, Jinge, Junru Chen, Jiayu Liang, et al.. (2025). Urogenital Manifestations in Mpox (Monkeypox) Infection: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Approaches. Infection and Drug Resistance. Volume 18. 209–226. 2 indexed citations

Li, Bingxin, et al.. (2025). Correlation study of PBK/TOPK expression, prognosis, and immune infiltration in breast cancer. Scientific Reports. 15(1). 15052–15052.

Chen, Junru, et al.. (2024). The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination therapy: A real-world study.. Journal of Clinical Oncology. 42(16_suppl). e16516–e16516.

Zeng, Hao, Xingming Zhang, Jiayu Liang, et al.. (2024). Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).. Journal of Clinical Oncology. 42(16_suppl). 4523–4523. 1 indexed citations

Zhao, Jinge, Ling Nie, Junru Chen, et al.. (2024). Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients. The Prostate. 85(2). 130–139.

Chen, Junru, Mengxin Zhang, Yahong Chen, et al.. (2024). Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma. npj Precision Oncology. 8(1). 261–261. 3 indexed citations

Pan, Xiuyi, Zilin Wang, Yahong Chen, et al.. (2024). Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma. European journal of medical research. 29(1). 378–378.

10.

Chen, Junru, Yuchen Huang, Yaowen Zhang, et al.. (2024). Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis. International Journal of Surgery. 110(6). 3923–3936. 6 indexed citations

11.

Wang, Qian, Xingming Zhang, Hong Zeng, et al.. (2024). Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor. International Urology and Nephrology. 57(5). 1433–1440.

12.

Chen, Junru, Guangxi Sun, Junjie Zhao, et al.. (2023). The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. Cancer Medicine. 12(24). 22370–22380. 5 indexed citations

13.

Zhu, Sha, Yige Bao, Linmao Zheng, et al.. (2022). Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report. OncoTargets and Therapy. Volume 15. 947–952. 1 indexed citations

14.

Chen, Junru, Yaowen Zhang, Xingming Zhang, et al.. (2022). Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. Frontiers in Pharmacology. 12. 789319–789319. 14 indexed citations

15.

Zhu, Xudong, Xingming Zhang, Guangxi Sun, et al.. (2021). Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. Cancer Management and Research. Volume 13. 6833–6845. 5 indexed citations

16.

Zhu, Sha, Guangxi Sun, Xiaolin Zhao, et al.. (2020). 650P Comparing the predictive value of exosome, circulating tumor cells, and tumor tissue in detecting AR-V7 among metastatic castration-resistant prostate cancer treated with abiraterone. Annals of Oncology. 31. S530–S530.

17.

Liu, Jiandong, Jinge Zhao, Mengni Zhang, et al.. (2019). <p>The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study</p>. Cancer Management and Research. Volume 11. 6521–6529. 5 indexed citations

18.

Chen, Junru, Zhipeng Wang, Jinge Zhao, et al.. (2019). Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Scientific Reports. 9(1). 17985–17985. 18 indexed citations

19.

Chen, Junru, Xingming Zhang, Guangxi Sun, et al.. (2018). The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. OncoTargets and Therapy. Volume 11. 9061–9070. 1 indexed citations

20.

Zhang, Xingming, Guangxi Sun, Jinge Zhao, et al.. (2018). Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. Journal of Cancer. 9(18). 3303–3310. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact